Bayer Nexavar Safety Profile Fuels Research In Multiple Cancer Indications

A dual mode of action and favorable safety profile will be the chief selling points for Bayer/Onyx' kidney cancer agent Nexavar (sorafenib), company officials said during Bayer's R&D investor conference in London Dec. 8

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet